ArticleFEBS open bio2019
Identification of potential diagnostic biomarkers for Parkinson's disease.
Article in FEBS open bio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 53 citations in OpenAlex.
- Alpha-like subunits of multisubunit RNA polymerases: insights into structure, function, and disease.RNA biology · 2026Review
- Decoding the Neuroinflammatory Potential of Non-Nutritive Sweeteners Through An Integrative Computational Approach.Neurotoxicity research · 2026Article
- Inherent variability limits clinical utility of reproducible Parkinson's transcriptomics signatures.NPJ Parkinson's disease · 2025Article
- A Theoretical and Practical Analysis of Membrane Protein Genes Altered in Neutrophils in Parkinson's Disease.Current issues in molecular biology · 2025Article
- Article
- The Role of ETNPPL in Dopaminergic Neuron Stability: Insights from Neuromelanin-Associated Protein Expression in Parkinson's Disease.International journal of molecular sciences · 2024Article
- Analysis ofBiomedicines · 2024Article
- Review
- Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson's disease models.Stem cell research & therapy · 2024Article
- Early-stage idiopathic Parkinson's disease is associated with reduced circular RNA expression.NPJ Parkinson's disease · 2024Article
- Blood biomarker-based classification study for neurodegenerative diseases.Scientific reports · 2023Article
- Multidimensional biomarkers for multiple system atrophy: an update and future directions.Translational neurodegeneration · 2023Review
- Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson's disease based on integrative analysis.NPJ Parkinson's disease · 2023Article
- Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson's Disease.Life (Basel, Switzerland) · 2023Review
- The Potential ofGenes · 2023Article
- Role and Dysregulation of miRNA in Patients with Parkinson's Disease.International journal of molecular sciences · 2022Article
- Light-Seq: light-directed in situ barcoding of biomolecules in fixed cells and tissues for spatially indexed sequencing.Nature methods · 2022Article
- Article
- Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease.NPJ Parkinson's disease · 2022Article
- Associations of ARHGAP26 Polymorphisms with Alzheimer's Disease and Cardiovascular Disease.Journal of molecular neuroscience : MN · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of biomarkers for early diagnosis of Parkinson's disease (PD) prior to the onset of symptoms may improve the effectiveness of therapy. To identify potential biomarkers, we downloaded microarray datasets of PD from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) between PD and normal control (NC) groups were obtained, and the feature selection procedure and classification model were used to identify optimal diagnostic gene biomarkers for PD. A total of 1229 genes (640 up-regulated and 589 down-regulated) were obtained for PD, and nine DEGs (PTGDS, GPX3, SLC25A20, CACNA1D, LRRN3, POLR1D, ARHGAP26, TNFSF14 and VPS11) were selected as optimal PD biomarkers with great diagnostic value. These nine DEGs were significantly enriched in regulation of circadian sleep/wake cycle, sleep and gonadotropin-releasing hormone signaling pathway. Finally, we examined the expression of GPX3, SLC25A20, LRRN3 and POLR1D in blood samples of patients with PD by qRT-PCR. GPX3, LRRN3 and POLR1D exhibited the same expression pattern as in our analysis. In conclusion, this study identified nine DEGs that may serve as potential biomarkers of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.